Eribulin in mTNBC Patients
NCT04541420 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 208
Last updated 2021-02-03
Summary
To evaluate the efficacy and safety of Eribulin in patients with advanced breast cancer.
Conditions
Sponsors & Collaborators
-
Fudan University
lead OTHER
Principal Investigators
-
Biyun Wang, Professor · Fudan University
Eligibility
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-12-15
- Primary Completion
- 2020-12-15
- Completion
- 2020-12-20
Countries
- China
Study Locations
More Related Trials
-
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
NCT04683445 ·Status: UNKNOWN
-
Treatment After Palbociclib-containing Regimens
NCT04517318 ·Status: COMPLETED
-
Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry
NCT02443428 ·Status: COMPLETED
-
Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer
NCT05402722 ·Status: UNKNOWN ·Phase: PHASE2
-
Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer
NCT05546255 ·Status: UNKNOWN ·Phase: PHASE2
-
An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer
NCT05186545 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer
NCT03583944 ·Status: COMPLETED ·Phase: PHASE4
-
A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and Taxanes
NCT03412955 ·Status: UNKNOWN ·Phase: PHASE2
-
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
NCT04544189 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
NCT04138719 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
NCT03437083 ·Status: COMPLETED
-
Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC
NCT04001634 ·Status: COMPLETED
-
Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies
NCT01142661 ·Status: COMPLETED ·Phase: NA
-
Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study
NCT04913571 ·Status: UNKNOWN ·Phase: PHASE2
-
Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
NCT06344780 ·Status: ACTIVE_NOT_RECRUITING
-
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
NCT03671330 ·Status: COMPLETED ·Phase: PHASE2
-
Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.
NCT04681287 ·Status: UNKNOWN ·Phase: PHASE2
-
Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)
NCT07255612 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Real World Study on the Efficacy and Safety of Anti-HER2 Therapy
NCT05367739 ·Status: COMPLETED
-
Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer
NCT02551263 ·Status: COMPLETED
-
Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer
NCT01961544 ·Status: COMPLETED ·Phase: PHASE4
-
Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib
NCT05464173 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
NCT05945368 ·Status: UNKNOWN ·Phase: PHASE2
-
Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer
NCT02549677 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer
NCT03854617 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2